Drug interaction study of vimseltinib in healthy men
Treatments studied
This study is for healthy men to see how a new drug called vimseltinib affects a protein in your body that helps remove other drugs. Participation will help your doctors understand how to use this drug safely in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male and in generally good health.
- Your body mass index (BMI) should be between 18 and 32.
- You must have normal blood and urine test results as evaluated by the study doctor.
- You must not have any significant medical conditions (such as heart, kidney, or liver disease).
- You must be willing to follow the study protocol and attend all visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medicine called vimseltinib changes how your body processes birth control pills. Understanding this interaction helps doctors know if the pill remains effective when taken together with this drug.
This study tests how another drug (carbamazepine) affects the amount of an investigational drug (verducatib) in the blood of healthy men. It helps determine if the drugs can be given together safely and how they interact.
This trial tests a new drug (VB19055) in healthy volunteers to see how safe it is and how the body processes it. Participants will be watched closely and may help find the right dose for future studies.
This early-stage study tests how a new experimental drug (BMS-986533) is processed and tolerated by healthy volunteers. Researchers will also check how food and stomach acid affect the drug, and whether it interacts with other medications.
This trial tests how flonoltinib tablets interact with other medicines or foods in healthy adults. Taking part helps doctors understand safe dosing and potential side effects before the drug is given to patients.
This trial tests a new drug called vimseltinib for people with active chronic graft versus host disease (cGVHD) that hasn't gotten better after at least two prior treatments. The goal is to see if vimseltinib can help control the condition.
Hear when a new Healthy Male Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.